Bank of America
RXRX icon

Bank of America’s Recursion Pharmaceuticals RXRX Stock Holding History

Bank of America’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.67M Buy
2,496,831
+384,486
+18% +$1.49M ﹤0.01% 3151
2025
Q4 		$8.64M Buy
2,112,345
+888,368
+73% +$4.4M ﹤0.01% 2965
2025
Q3 		$5.97M Sell
1,223,977
-154,938
-11% -$814K ﹤0.01% 3816
2025
Q2 		$6.98M Buy
1,378,915
+93,953
+7% +$462K ﹤0.01% 3561
2025
Q1 		$6.8M Buy
1,284,962
+402,098
+46% +$2.93M ﹤0.01% 3514
2024
Q4 		$5.97M Sell
882,864
-282,561
-24% -$1.9M ﹤0.01% 3417
2024
Q3 		$7.68M Sell
1,165,425
-676,040
-37% -$4.85M ﹤0.01% 3326
2024
Q2 		$13.8M Buy
1,841,465
+138,551
+8% +$1.21M ﹤0.01% 2618
2024
Q1 		$17M Buy
1,702,914
+917,637
+117% +$10.2M ﹤0.01% 2450
2023
Q4 		$7.74M Sell
785,277
-113,483
-13% -$809K ﹤0.01% 3155
2023
Q3 		$6.88M Buy
898,760
+668,042
+290% +$6.66M ﹤0.01% 3107
2023
Q2 		$1.72M Sell
230,718
-326,292
-59% -$2.28M ﹤0.01% 4343
2023
Q1 		$3.72M Buy
557,010
+135,146
+32% +$1.07M ﹤0.01% 3806
2022
Q4 		$3.25M Buy
421,864
+222,998
+112% +$2.19M ﹤0.01% 3803
2022
Q3 		$2.12M Buy
198,866
+92,649
+87% +$938K ﹤0.01% 4218
2022
Q2 		$864K Buy
106,217
+22,537
+27% +$151K ﹤0.01% 5036
2022
Q1 		$599K Sell
83,680
-87,495
-51% -$930K ﹤0.01% 5695
2021
Q4 		$2.93M Buy
171,175
+144,668
+546% +$2.72M ﹤0.01% 4186
2021
Q3 		$610K Buy
26,507
+18,630
+237% +$528K ﹤0.01% 5485
2021
Q2 		$288K Buy
+7,877
New +$233K ﹤0.01% 5827

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America's RXRX Position: Q1 2026 in Review

Bank of America increased its Recursion Pharmaceuticals (RXRX) stake by 18% in Q1 2026, buying an estimated $1.49M and bringing the position to 2,496,831 shares worth $7.67M. The position accounts for ﹤0.01% of the portfolio, ranked #3151.

Bank of America first reported a position in RXRX in Q2 2021 and has held it in 20 quarters since. The position peaked at $17M in Q1 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Bank of America held 2,496,831 shares of Recursion Pharmaceuticals worth $7.67M as of Q1 2026.
  • Bank of America bought 384,486 Recursion Pharmaceuticals shares in Q1 2026, an estimated $1.49M.
  • Recursion Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3151 holding.
  • Bank of America first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • Bank of America's Recursion Pharmaceuticals position peaked at $17M in Q1 2024.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.